Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05290363 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

Study acronym: SpA23
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Mar 15, 2026 to Sep 30, 2027
    • Study sites: 1 to 4
    • Eligibility criteria shortened, about 40 words
    • Study description expanded, about 8 words
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Mar 15, 2023 to Mar 15, 2026
    • Start date changed from estimate of Apr 15, 2022 to Oct 6, 2022
    • Site details revised
    v3
  4. Start date: Mar 15, 2022 to Apr 15, 2022
    • Primary endpoints revised (5)
    • Secondary endpoint revised
    • Study arms: 1 to 2
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
Trial Details
NCT Number NCT05290363
Lead Sponsor Institut Pasteur
Collaborators: Janssen Biotech, Inc.
Conditions
(from sponsor)		 Spondyloarthritis
Related terms Spondylarthritis
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov